Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Supernus Pharmaceuticals ...

    NASDAQ: SUPN · Real-Time Price · USD
    32.46
    0.43 (1.34%)
    At close: Jun 16, 2025, 3:59 PM
    33.25
    2.43%
    After-hours: Jun 16, 2025, 05:54 PM EDT
    1.34%
    Bid 30.08
    Market Cap 1.82B
    Revenue (ttm) 668M
    Net Income (ttm) 61.91M
    EPS (ttm) 1.11
    PE Ratio (ttm) 29.24
    Forward PE 13.09
    Analyst Hold
    Ask 34
    Volume 847,040
    Avg. Volume (20D) 511,682
    Open 32.33
    Previous Close 32.03
    Day's Range 31.80 - 33.13
    52-Week Range 25.55 - 40.28
    Beta 0.71

    About SUPN

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol SUPN
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for SUPN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    3 months ago
    -15.67%
    Supernus Pharmaceuticals shares are trading lower ... Unlock content with Pro Subscription
    3 months ago
    +1.64%
    Supernus Pharmaceuticals shares are trading lower after the company announced that the Phase 2b study of SPN-820 in adults with treatment-resistant depression did not demonstrate a statistically significant improvement on the primary endpoint of change from baseline in the Montgomery-Åsberg Depression Rating Scale.
    news image

    18 hours ago · reuters.com

    Supernus Pharma to acquire Sage Therapeutics in up to $795 million deal

    Drugmaker Supernus Pharmaceuticals said on Monday it will acquire Sage Therapeutics , which makes treatments for neurological conditions, in a deal worth up to $795 million.

    news image

    1 month ago · zacks.com

    Is the Options Market Predicting a Spike in Supernus Pharmaceuticals (SUPN) Stock?

    Investors in Supernus Pharmaceuticals, Inc. SUPN need to pay close attention to the stock based on moves in the options market lately. That is because the June 20, 2025 $30 Call had some of the highes...

    news image

    1 month ago · accessnewswire.com

    Lost Money on Supernus Pharmaceuticals, Inc. (SUPN)? Contact Levi & Korsinsky Regarding an Ongoing Investigation

    NEW YORK, NY / ACCESS Newswire / May 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S...

    news image

    1 month ago · accessnewswire.com

    Levi & Korsinsky Reminds Supernus Pharmaceuticals, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - SUPN

    NEW YORK, NY / ACCESS Newswire / May 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S...

    news image

    1 month ago · accessnewswire.com

    SUPN STOCK ALERT: Levi & Korsinsky Notifies Supernus Pharmaceuticals, Inc. Investors of an Ongoing Investigation

    NEW YORK, NY / ACCESS Newswire / May 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S...

    news image

    1 month ago · seekingalpha.com

    Supernus Pharmaceuticals, Inc. (SUPN) Q1 2025 Earnings Call Transcript

    Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2025 Earnings Conference Call May 6, 2025 4:30 PM ET Company Participants Peter Vozzo - Investor Relations-ICR Healthcare Jack Khattar - Chief Executiv...

    news image

    1 month ago · zacks.com

    Supernus (SUPN) Reports Q1 Earnings: What Key Metrics Have to Say

    The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimat...

    news image

    1 month ago · zacks.com

    Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Surpass Estimates

    Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.42 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to break-even earnings per share a year ago.

    news image

    1 month ago · accessnewswire.com

    Investors who Lost Money on Supernus Pharmaceuticals, Inc. Should Contact Levi & Korsinsky About an Ongoing Investigation - SUPN

    NEW YORK, NY / ACCESS Newswire / May 6, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S...

    news image

    1 month ago · accessnewswire.com

    Supernus Pharmaceuticals, Inc. (SUPN) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

    NEW YORK, NY / ACCESS Newswire / May 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals, Inc.") (NASDAQ:S...

    Add to Watchlist